Overview

Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
Phase:
Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborator:
Nycomed
Treatments:
Pantoprazole